Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helena Harlin

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Prostate|October 24, 2008
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancerDavid Knight, Amy C Peterson, Brian I Rini, et al.
European Journal of Immunology|September 5, 2002
CTLA-4 engagement regulates NF-kappaB activation in vivoHelena Harlin, Kwang Woo Hwang, David A Palucki, et al.
Cancer Research|March 19, 2009
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitmentHelena Harlin, Yuru Meng, Amy C Peterson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2007
The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subsetHelena Harlin, Mikael Hanson, C Christian Johansson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignanciesTodd M Zimmerman, Helena Harlin, Olatoyosi M Odenike, et al.
Investigational New Drugs|March 4, 2006
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinomaAmy C Peterson, Helena Harlin, Theodore Karrison, et al.
Cancer Immunology, Immunotherapy : CII|November 29, 2008
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanomaC Christian Johansson, Suzanne Egyházi, Giuseppe Masucci, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Prostate|October 24, 2008
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancerDavid Knight, Amy C Peterson, Brian I Rini, et al.
European Journal of Immunology|September 5, 2002
CTLA-4 engagement regulates NF-kappaB activation in vivoHelena Harlin, Kwang Woo Hwang, David A Palucki, et al.
Cancer Research|March 19, 2009
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitmentHelena Harlin, Yuru Meng, Amy C Peterson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2007
The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subsetHelena Harlin, Mikael Hanson, C Christian Johansson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignanciesTodd M Zimmerman, Helena Harlin, Olatoyosi M Odenike, et al.
Investigational New Drugs|March 4, 2006
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinomaAmy C Peterson, Helena Harlin, Theodore Karrison, et al.
Cancer Immunology, Immunotherapy : CII|November 29, 2008
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanomaC Christian Johansson, Suzanne Egyházi, Giuseppe Masucci, et al.
Pageof 2